(Q34594335)

3 August 2017

Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial (English)

1 reference

juvenile rheumatoid arthritis

3 August 2017

0 references

1 reference

8

Ruben Burgos-Vargas

0 references

Pierre Quartier

object named as

Pierre Quartier

3

0 references

Nicolino Ruperto

1

object named as

Nicolino Ruperto

1 reference

3 August 2017

Carlos Abud-Mendoza

7

1 reference

ORCID Public Data File 2021

Clovis A Silva

6

object named as

Clovis A Silva

1 reference

3 August 2017

27

Alberto Martini

1 reference

3 August 2017

2

Daniel J Lovell

1 reference

3 August 2017

28

Edward H Giannini

1 reference

3 August 2017

18

Philip J Hashkes

1 reference

3 August 2017

Eliana Paz

4

1 reference

3 August 2017

Nadina Rubio-Pérez

5

1 reference

3 August 2017

Ruben Burgos-Vargas

8

1 reference

3 August 2017

Valeria Gerloni

9

1 reference

3 August 2017

Jose A Melo-Gomes

10

1 reference

3 August 2017

Claudia Saad-Magalhães

11

1 reference

3 August 2017

Flavio Sztajnbok

12

1 reference

3 August 2017

Claudia Goldenstein-Schainberg

13

1 reference

3 August 2017

Morton Scheinberg

14

1 reference

3 August 2017

Immaculada Calvo Penades

15

1 reference

3 August 2017

Michael Fischbach

16

1 reference

3 August 2017

Javier Orozco

17

1 reference

3 August 2017

Christine Hom

19

1 reference

3 August 2017

Lawrence Jung

20

1 reference

3 August 2017

Loredana Lepore

21

1 reference

3 August 2017

Sheila Oliveira

22

1 reference

3 August 2017

Carol A Wallace

23

1 reference

3 August 2017

Leonard H Sigal

24

1 reference

3 August 2017

Alan J Block

25

1 reference

3 August 2017

Allison Covucci

26

1 reference

3 August 2017

Paediatric Rheumatology INternational Trials Organization

29

1 reference

3 August 2017

Pediatric Rheumatology Collaborative Study Group

30

1 reference

3 August 2017

language of work or name

English

0 references

publication date

14 July 2008

1 reference

3 August 2017

1 reference

3 August 2017

372

1 reference

3 August 2017

9636

1 reference

3 August 2017

383-391

1 reference

Proxy-reported health-related quality of life of patients with juvenile idiopathic arthritis: The pediatric rheumatology international trials organization multinational quality of life cohort study

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960998-8

7 January 2021

Juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960998-8

7 January 2021

Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960998-8

7 January 2021

A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960998-8

7 January 2021

Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960998-8

7 January 2021

A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960998-8

7 January 2021

The German etanercept registry for treatment of juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960998-8

7 January 2021

Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960998-8

7 January 2021

Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960998-8

7 January 2021

Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960998-8

7 January 2021

Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960998-8

7 January 2021

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960998-8

7 January 2021

Measurement of health status in children with juvenile rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960998-8

7 January 2021

Preliminary definition of improvement in juvenile arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960998-8

7 January 2021

International research networks in pediatric rheumatology: the PRINTO perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960998-8

7 January 2021

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960998-8

7 January 2021

10.1016/S0140-6736(08)60998-8

Identifiers

DOI

1 reference

3 August 2017

1 reference